Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151292 | 0.86 | KDM4E (0.55) | TSHRKDM4EL3MBTL1FFAR1ALDH1A1 | |
| SCHEMBL27965449 | 0.84 | KDM4E (0.43) | AOC3TSHRKDM4EL3MBTL1FFAR1 | |
| SCHEMBL6978184 | 0.83 | AOC3 (0.48) | AOC3TSHRL3MBTL1FFAR1MAPK1 | |
| SCHEMBL1548251 | 0.83 | AOC3 (0.48) | AOC3TSHRL3MBTL1FFAR1MAPK1 | |
| SCHEMBL8590346 | 0.83 | AOC3 (0.48) | AOC3TSHRL3MBTL1FFAR1MAPK1 | |
| SCHEMBL6975924 | 0.83 | AOC3 (0.48) | AOC3TSHRL3MBTL1FFAR1MAPK1 | |
| SCHEMBL6055352 | 0.82 | TP53 (0.52) | TSHRKDM4EL3MBTL1UGT2B7MAPK1 | |
| SCHEMBL15074874 | 0.82 | AOC3 (0.50) | AOC3KDM4EL3MBTL1MAPK1LMNA | |
| SCHEMBL27569844 | 0.82 | PTGS1 (0.49) | KDM4EL3MBTL1FFAR1ALDH1A1LMNA | |
| SCHEMBL4392498 | 0.82 | BRD4 (0.39) | AOC3TSHRUGT2B7FFAR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | AOC3 455/4885TSHR 368/4885KDM4E 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.